-
Mashup Score: 3The Landmark Series: Cancer Vaccines for Solid Tumors - 5 hour(s) ago
Annals of Surgical Oncology – Immunotherapy has become an integral part of the treatment for solid tumors. Cancer vaccines represent a potentially powerful class of immunotherapeutic agents to…
Source: link.springer.comCategories: General Medicine NewsTweet
-
Mashup Score: 4SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances - 15 hour(s) ago
Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma and currently considered incurable with standard therapies. 1 The majority of patients present with advanced disease, and many of them are asymptomatic at diagnosis. Current guidelines for management include active surveillance or rituximab monotherapy for patients who present with low–tumor burden FL. 2 Data from the National LymphoCare study show that active surveillance and rituximab monotherapy are commonly applied for this
Source: ascopubs.orgCategories: General Medicine NewsTweet-
A "Trials in Progress" article -- the first in JCO Oncology Advances: SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances https://t.co/HXZkmoe0dx
-
-
Mashup Score: 4
Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma and currently considered incurable with standard therapies. 1 The majority of patients present with advanced disease, and many of them are asymptomatic at diagnosis. Current guidelines for management include active surveillance or rituximab monotherapy for patients who present with low–tumor burden FL. 2 Data from the National LymphoCare study show that active surveillance and rituximab monotherapy are commonly applied for this
Source: ascopubs.orgCategories: General Medicine NewsTweet-
A "Trials in Progress" article -- the first in JCO Oncology Advances: SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances https://t.co/HXZkmoe0dx
-
-
Mashup Score: 3An ASCO Hill Day in Interesting Times | SWOG - 9 day(s) ago
Overall, the mood of this Hill Day was cautious, but it was peppered with moments of optimism as well. ASCO had set three goals for our collective lobbying efforts:
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: An @ASCO Hill Day in Interesting Times I was in DC last week to advocate for consistent+ funding for NIH, @theNCI, and ARPA-H in FY2026 and for other policies important to cancer research & to patients with cancer. #ASCOAdvocacySummit https://t.co/9ExFuOkAS1 https://t.co/dATSv28ycg
-
-
Mashup Score: 4
“We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care,” says Michael S. Cookson, MD, MMHC, FACS.
Source: www.urologytimes.comCategories: General Medicine NewsTweet-
"Among the most notable federally funded trials are those that revolutionized bladder cancer treatment, such as the SWOG 8507 trial, ..." The Importance of Federal Funding in Cancer Research: A Call to Action https://t.co/sgIG3QHCEY via @urologytimes
-
-
Mashup Score: 4TM Link of the Week: When Things Just Click | SWOG - 18 day(s) ago
In San Francisco, the consolidated plenary’s first segment (after my chair’s update) will be led by Dr. Lee Ellis, SWOG’s vice chair of TM, and will feature two speakers on TM work at SWOG. My first group meeting as SWOG chair, in spring 2013, featured a TM symposium led by Dr. Ellis, with Dr. James Rae, our executive officer for TM, as one of several speakers. And Drs. Ellis and Rae have been planning and providing cutting-edge TM content to SWOG members ever since, at Plenary 1 and beyond.
Source: www.swog.orgCategories: General Medicine NewsTweet-
Our @SWOGChair blog: TM Link of the Week: When Things Just Click Our TM leadership has brought many symposia, workshops, retreats, & plenaries to members. For 12 yrs now, they've also delivered a curated high-value TM article each week to busy clinicians. https://t.co/pJo0g21XEQ https://t.co/CTz7GNVaYa
-
-
Mashup Score: 8NCCS to Recognize Susan Leigh, BSN, RN and Desirée Walker with 2025 Ellen L. Stovall Award - NCCS - National Coalition for Cancer Survivorship - 20 day(s) ago
The National Coalition for Cancer Survivorship (NCCS) is proud to announce the recipients of the 2025 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care: Susan Leigh, BSN, RN-Retired – Health Care Professional Award Desirée A.H. Walker – Patient Advocate Award The Ellen L. Stovall Award, named in honor of longtime NCCS CEO and […]
Source: canceradvocacy.orgCategories: General Medicine NewsTweet-
Congratulations to @SWOG patient advocate @MzDesNY on being recognized with the 2025 Ellen Stovall Award for Innovation in Patient-Centered Care by the National Coalition for Cancer Survivorship @canceradvocacy! https://t.co/ADcW6qoAwv
-
-
Mashup Score: 1Meet the Advocate: Anne Marie Mercurio | SWOG - 1 month(s) ago
Anne Marie was diagnosed in the spring of 2006 with invasive lobular breast cancer. Eight rounds of chemo followed (as did a decade of endocrine therapy). That chemo took the toll it too often takes: in her words, “I knew my brain was scrambled [by it]”. She turned to a clinical trial of an intervention designed to help those suffering from chemo brain. She found, though, that the eligibility criteria were so restrictive that she “failed” the trial’s cognitive assessment for entry, scoring higher than the allowed cutoff.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair's blog: Meet the Advocate: Anne Marie Mercurio Anne Marie Mercurio, co-chair of @SWOG’s patient advocate committee since October 2023, has been a social media pioneer in advocating for those with cancer. @chemobrainfog https://t.co/SUaBa1KYab
-
-
Mashup Score: 3Spring Group Meeting: Shorter, But Sweeter | SWOG - 2 month(s) ago
We have consolidated our group meeting schedule from four days to three, starting in spring of 2025. That meeting will run Thursday to Saturday, May 1st – 3rd, at the Hyatt Regency San Francisco. Registration opens SOON! Look for it on February 25th. Here’s a preview of the schedule (the meeting site will go live closer to registration day).
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Spring Group Meeting: Shorter, But Sweeter We've consolidated our group meeting schedule from 4 days to 3, starting in spring of 2025. We think this change will deliver substantial benefits, including a significant reduction in costs. https://t.co/SUjtBVyB1L https://t.co/1vQpDMKFgr
-
-
Mashup Score: 5Results of S1613: HER2 Inhibitors for HER2+ CRC | SWOG - 3 month(s) ago
The study compared treatment with dual HER2 inhibitors to a standard EGFR inhibitor-based treatment in patients with previously treated, HER2-positive disease. It found that the HER2 inhibitor treatment can provide similar benefit with less toxicity.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Results of S1613: HER2 Inhibitors for HER2+ mCRC Our S1613 trial results are out in @JCO_ASCO. Particularly intriguing -- relative benefit of dual HER2 inhibitors vs EGFR inhibitor tx seems tied to the level of HER2 amplification. https://t.co/BVMv2GifSn https://t.co/Brs9eLHIGU
-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: The Landmark Series: Cancer Vaccines for Solid Tumors https://t.co/LbU7p7XCO2 https://t.co/llA0CMfICl